Today: 28 February 2026
Subscribe
Browse Category

NYSE:NUVB 19 November 2025 - 11 December 2025

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio shares surged nearly 200% year-to-date, trading around $7.84 on December 11, 2025, after FDA approval of its lung cancer drug IBTROZI and strong analyst upgrades. H.C. Wainwright raised its price target to $18, citing higher revenue forecasts and clinical results. Average daily volume reached 8.7 million shares. The company reported 204 new patients started IBTROZI in Q3.
11 December 2025
Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

Nuvation Bio shares surged about 50% to $7.20 in early afternoon trading Wednesday after B. Riley Securities initiated coverage with a “Buy” rating and $12 price target. The rally followed strong commercial results for lung cancer drug IBTROZI and coincided with management’s presentation at the Jefferies Global Healthcare Conference in London. Trading volume hit tens of millions of shares, lifting the company’s market cap to $2.4 billion.
19 November 2025
··
Go toTop